Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154599 | 1.00 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL15663456 | 1.00 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| Ammonia Solution, Strong SCHEMBL15303247 | 0.98 | FAAH (0.36) | FAAH | |
| SCHEMBL12629160 | 0.83 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL10980085 | 0.83 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL16234969 | 0.80 | FAAH (0.35) | FAAH | |
| SCHEMBL4480182 | 0.80 | FAAH (0.35) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL19746826 | 0.80 | FAAH (0.35) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL22030293 | 0.80 | CTSL (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL10988574 | 0.80 | CTSL (0.37) | FAAHCTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-04-11 | — | — | US | disclosed |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2346871-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BioLab Corporation (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2303887-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism Biolab Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010044485-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | PRISM BIOLAB CORPORATION (JP) | 2010-04-22 | — | — | WO | disclosed |
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2009148192-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | FAAH 3696/4885CTSL 1598/4885CTSB 1443/4885 |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | FAAH 2876/4885CTSL 2965/4885CTSB 1127/4885 |
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | ADRA1D, ADRA1A, ADRB1 | FAAH 1071/4885CTSL 3480/4885CTSB 3795/4885 |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | TUBB1, TUBA1B, TUBA1C | FAAH 4221/4885CTSL 4683/4885CTSB 4096/4885 |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | FAAH 1257/4885CTSL 2010/4885CTSB 1017/4885 |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | FAAH 1251/4885CTSL 2002/4885CTSB 1014/4885 |
| US-20110092459-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | COL1A1, PLOD3, THPO | FAAH 3219/4885CTSL 717/4885CTSB 1266/4885 |
| US-20110263607-A1 | ALPHA HELIX MIMETICS IN THE TREATMENT OF CANCER | COL1A1, HDGF, HCCS | FAAH 4052/4885CTSL 1385/4885CTSB 1921/4885 |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | DYRK1B, DYRK3, DYRK2 | FAAH 3416/4885CTSL 3146/4885CTSB 2111/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | FAAH 4189/4885CTSL 2492/4885CTSB 2287/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | FAAH 4546/4885CTSL 1442/4885CTSB 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.